Philips Respironics: Call Centers, Loans and Referral Benefits

The Respironics kickback settlement announced in 2016 required the company to pay $34.8 million over alleged free call center services for suppliers buying its sleep-apnea masks. Three later settlements addressed free prescribing data, supplier financing and masks supplied to sleep laboratories. For someone inside the respiratory equipment business, the connection is familiar: a manufacturer can win a product recommendation by paying for something the supplier or referral source would otherwise have to buy.

Respironics Inc., later named Philips RS North America LLC, manufactures durable medical equipment. Its different kickback settlements in 2016, 2022 and 2023 followed benefits supplied at different points between the manufacturer, the supplier and the prescribing physician.

Free Manufacturer Call Center Services for CPAP Mask Buyers

Free manufacturer call center services for CPAP mask buyers were the alleged inducement behind the first settlement. In its March 23, 2016 announcement, the Department of Justice said Respironics offered suppliers patient-resupply services without charge when patients used Respironics masks. A supplier serving patients with a competitor’s mask had to pay a monthly fee based on those patients.

The government alleged that the arrangement ran from April 2012 through November 2015. The service helped suppliers meet patients’ resupply needs, while the choice of mask determined the supplier’s service bill. A rival manufacturer’s mask carried an operating cost that the Respironics mask avoided. The alleged arrangement put competing mask makers at a disadvantage and left taxpayers paying claims influenced by the supplier’s savings.

The whistleblower’s complaint challenged the idea that medSage, the resupply call-center service, was already paid for in the mask price:

The complaint also described a supplier owner who said tight margins made medSage necessary to save money. According to the whistleblower, the owner indicated that he would continue moving existing patients from competing masks to Respironics masks and start new patients on Respironics equipment and supplies. The alleged sales advantage reached both patients already on therapy and those just entering the business.

That matters because the machine begins a relationship that replacement supplies sustain. Under Medicare’s CPAP coverage policy, a CPAP device becomes the patient’s property after thirteen paid rental months. Masks, cushions, tubing, filters and headgear remain a separate recurring supply business. A service that handles resupply sits beside those repeat orders, giving the manufacturer an opportunity to influence more than the first equipment purchase.

The case began with a whistleblower who had worked for different durable medical equipment companies. The settlement allocated $5.38 million to that whistleblower out of the federal share of the recovery. The insider knew the supplier’s costs and product decisions, the part of the transaction a Medicare claim alone would not explain.

The 2022 Settlement Over Free Prescribing Data

The 2022 Respironics kickback settlement addressed free physician-prescribing data supplied to durable medical equipment companies. The Department of Justice announced the resolution on September 1, 2022, with $22.62 million payable to the United States and $2.13 million payable to states for their Medicaid programs.

The government alleged that the free data helped suppliers market to physicians and caused false claims to Medicare, Medicaid and TRICARE. The equipment included ventilators, oxygen concentrators, CPAP and BiPAP machines. The manufacturer’s alleged influence began before the supplier submitted the bill, with information that could help the supplier bring in business.

The whistleblower’s complaint explained the exchange. Respironics allegedly bought valuable information about physicians’ prescribing decisions and gave it to suppliers, which could use it to identify local physicians to approach. In return, the complaint alleged, Respironics wanted suppliers to recommend its products to physicians and patients.

The complaint put a price on comparable access through VGM Market Data: buying all four products nationwide would cost $160,000 per year. Access to data could be a substantial sales benefit even when the manufacturer sent the supplier no money.

A sales representative allegedly recorded in Salesforce that he had reviewed data with a supplier to target accounts doing business with competitors. According to the complaint, the supplier left with leads to pursue.

The Complaint Says Employees Questioned the Data Sharing

The complaint alleged that Respironics employees questioned whether sharing the data was an inducement and that managers authorized it anyway. It also quoted an internal instruction about the data vendor’s contract:

The whistleblower alleged that, after the July 2017 warning about violating the data vendor’s contract, employees became more cautious about describing the sharing in writing while the practice continued.

In December 2018, according to the complaint, subordinates told a sales director they were uncomfortable supplying updated data because they feared it could be seen as an inducement. After consulting the vice president of sales, the director allegedly gave this instruction:

Letting a customer copy the information still gives the customer the information. That is what makes the alleged instruction revealing: the concern had reached management, and the response described another way to deliver the same benefit.

The Justice Department identified a Respironics employee as the whistleblower behind this case and announced a reward of approximately $4.3 million from the federal settlement amount. This was a different whistleblower case from the earlier call-center case.

A DME Supplier Interest-Free Loan With the Risk on Respironics

A DME supplier interest-free loan backed in full by its manufacturer was the subject of a separate settlement announced on September 22, 2022. Respironics agreed to pay $1,283,825 over the government’s allegation that it helped a supplier obtain a twelve-month, interest-free loan and took on the full financial risk if the supplier failed to repay it.

The alleged arrangement ran between December 2015 and December 2016. Its value to the supplier had two parts: borrowing without interest and having the manufacturer carry the risk of non-collection. Credit support can influence a purchasing decision as directly as a service the supplier receives for free.

The government contended that the financing unlawfully induced referrals for Respironics equipment. A whistleblower brought this case, and the announcement said the whistleblower would share in the government’s recovery.

The Sleep-Lab Mask Allegation

Free masks supplied to sleep laboratories were the alleged benefit behind the December 22, 2023 settlement. Philips Respironics paid $2,471,359 to resolve allegations that, from 2016 through 2021, it gave labs masks used to diagnose and treat sleep-related respiratory disorders to induce their physicians to refer or prescribe Respironics-brand masks.

Here, the alleged benefit reached the place where the physician’s recommendation originated. Suppliers would then fill those prescriptions and bill federal health care programs. In the government’s account, the lab received the free goods, the physician directed the product choice, and a supplier submitted the claim.

That sequence explains why a manufacturer can face a False Claims Act case over a bill another business submits. The government’s allegation connected the free masks at the sleep lab to the brand prescribed and the equipment later billed. An employee working with labs could see the first part of that arrangement while a supplier employee saw its effect on orders.

What the Independent Monitor Was Meant to Watch

The 2022 settlements came with a five-year corporate integrity agreement requiring review of arrangements with referral sources and monitoring of Respironics’ sales force. The Justice Department also described a requirement to retain an independent monitor, selected by the HHS Office of Inspector General, to assess the effectiveness of the company’s compliance systems.

Its focus on referral arrangements and sales activity fits the allegations: the decisions affecting federal claims occurred in commercial relationships before the supplier billed for equipment.

That is the value of the complaint’s sales notes, internal instructions and employee concerns. They describe what the customer received, why the sales team offered it and what managers knew. Those are the connections our whistleblower experts examine with someone who knows the arrangement from inside.

ResMed Faced Similar Allegations

ResMed‘s January 15, 2020 settlement exceeded $37.5 million and addressed allegations involving free patient-outreach services, free or below-cost equipment for sleep labs, and interest-free supplier financing backed by the manufacturer. The overlap shows why the commercial benefit matters: resupply services, equipment and credit can each help a manufacturer influence the business that reaches its products.

The wider enforcement picture includes both sides of that relationship. In its 2024 report on Medicaid Fraud Control Units, hosted by AAPC, the HHS Office of Inspector General reported that medical-device manufacturers and durable medical equipment suppliers accounted for more civil settlements and judgments than other provider types in fiscal year 2023. The government’s durable medical equipment-fraud work reaches the maker as well as the company sending the claim.

For an insider, the Respironics cases give that distinction a concrete shape. The relevant knowledge may sit with the employee who priced the resupply service, the sales representative who shared the data, the team that arranged financing or the staff supplying masks to sleep labs. We work with that knowledge to connect the benefit, the intended business and the claims it generated.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Customer Received

Your knowledge of the sales arrangement is where our work together starts. Speak to one of our Whistleblower Experts about what the customer received and what the manufacturer expected in return. We stay alongside you throughout the case, bringing in healthcare fraud whistleblower lawyers who know equipment sales to build your strongest kickback whistleblower case.